Supporting evidence

• LedgerRevenue growth acceleration (+13.0% YoY)
• LedgerMixed quarter based on: Revenue growth acceleration (+13.0% YoY) · EPS growth pressure (-47.5% YoY).
• LedgerRevenue +13% YoY (Q2 FY2026)

• EventEstablishes Abbott as a leader in the oncology diagnostics market and adds a new high-growth vertical to Abbott's portfolio. Expected to cause $0.20 dilution to full-year 2026 adju…
• EventIndicates potential for a new product to reduce stroke risk in AFib patients, contributing to the Medical Devices segment.
• EventEnhances Abbott's internal reporting and oversight framework for legal and regulatory compliance.
• InitiativeAdopting governance reforms and enhancing Abbott’s internal reporting and oversight framework for legal and regulatory compliance as part of a settlement.
• InitiativeAcquisition completed, now integrating to achieve leadership position.
• InitiativePositive early results announced.
• InitiativeProjected to go live by the end of 2025.